Rozbor firmy
Merck (MRK): Keytruda, oncology and the moat of a pharmaceutical giant
Key takeaways
- Keytruda (pembrolizumab) is the world's best-selling oncology drug and accounts for the overwhelming majority of Merck's revenue.
- Merck is intensively seeking a successor to Keytruda and expanding its pipeline through acquisitions (Prometheus, Acceleron).
- The expiry of Keytruda's patent is the key risk for the coming decade — monitor the progress of biosimilars.
- A secondary division includes veterinary products (Merck Animal Health) — a more stable but smaller revenue source.
- Healthcare ETFs (XDWH) provide Merck exposure alongside dozens of other pharmaceutical names.
Merck & Co. (MRK) is an American pharmaceutical giant whose business is today largely driven by a single product — the oncology drug Keytruda. This concentration is simultaneously its strength and its key risk.
Keytruda: the global oncology leader
Keytruda (pembrolizumab) is an immunotherapy drug approved for dozens of tumour types. Its success transformed Merck from an average pharmaceutical player into one of the most profitable healthcare companies in the world. Keytruda works by "releasing the brakes" on the immune system so it attacks tumour cells — a principle that opened an entirely new class of cancer treatment.
Economic moat
Merck's moat rests on a combination of strong patents, clinical data (over a thousand ongoing studies) and a salesforce capable of bringing results to market. Keytruda has approvals across so many indications that each new positive study result expands its addressable market without the need to develop a new molecule.
Risks
- Patent cliff: Keytruda's key patent is expiring — biosimilars could significantly reduce revenue.
- Revenue concentration: dependence on a single product is extraordinary even among pharmaceutical giants.
- Pipeline uncertainty: if key clinical trials for a successor fail, the impact on the share price will be direct and swift.
- Price regulation: pressure to lower drug prices under Medicare (IRA) may weigh on margins.
Investment thesis and ETFs
Merck is an example of a company with an exceptional current position but a visible risk on a five-to-ten-year horizon. Investors who believe in management's ability to renew the pipeline and hold a direct position may use MRK as a dividend anchor. Those unwilling to accept this concentrated risk prefer a healthcare ETF such as XDWH. A comparison of both approaches can be found in the article on active vs. passive investing, and a fund overview in the ETF overview.
FAQ
What is Keytruda and why is it so important for Merck?
Keytruda is an immunotherapy oncology drug approved for dozens of cancer types. It is the world's best-selling oncology drug and accounts for a large share of Merck's revenue — making its future critical to the value of the entire company.
When does the Keytruda patent expire?
Key patents are losing protection approximately in the second half of the 2020s. The exact date depends on the indication and geography — verify in current analytical materials, as the situation is evolving.
Does Merck pay a strong dividend?
Merck historically pays a regular dividend and is included in indices tracked by dividend investors. Verify the specific yield in current data — dividends depend on earnings, which may be affected by Keytruda's development.